Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VOLTAREN ARTHRITIS PAIN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Relief of pain and inflammation associated with osteoarthritis,Relief of pain and inflammation associated with rheumatoid arthritis,Relief of pain and inflammation associated with ankylosing spondylitis,Acute pain (including migraine),Dysmenorrhea
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
Approximately 2 hours; terminal half-life may be prolonged in elderly (up to 4 hours) or hepatic impairment.
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Hepatic metabolism via CYP2C9; also undergoes conjugation (glucuronidation) and hydroxylation.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
>99% bound to albumin.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
0.1–0.2 L/kg; primarily distributes to synovial fluid (concentrations up to 50% of plasma).
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral: 100% (immediate-release); topical: approximately 6% systemic absorption.
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
GFR >30 m L/min: no adjustment. GFR 10-30 m L/min: dose reduction to 50 mg once daily or avoid use. GFR <10 m L/min: contraindicated.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 75 mg/day). Child-Pugh C: contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
For juvenile idiopathic arthritis: 1-2 mg/kg/day in 2-3 divided doses, maximum 3 mg/kg/day or 150 mg/day. For children <1 year: not recommended.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Start at lowest effective dose (e.g., 50 mg once daily). Increase cautiously; maximum 100 mg/day. Monitor renal function and GI bleeding risk.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure and edema; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; ophthalmic effects; hepatic effects; asthma; masking of inflammation and fever.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; pregnancy (third trimester); history of gastrointestinal bleeding or perforation related to previous NSAID therapy; active peptic ulcer disease; severe heart failure; known hypersensitivity to diclofenac or any component of the product.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
No specific food interactions with topical diclofenac. However, high-fat meals may increase systemic absorption if gel is applied over large areas; advise avoiding excessive intake of fatty foods when using large doses. Alcohol may increase risk of gastrointestinal irritation if oral NSAIDs are taken concurrently; avoid excessive alcohol consumption.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairment. Third trimester: High risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios; contraindicated after 30 weeks gestation.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Limited excretion into breast milk (M/P ratio approximately 0.02-0.04). Considered compatible with breastfeeding due to low infant dose (<0.1% of maternal weight-adjusted dose); monitor infant for gastrointestinal effects.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
No specific pharmacokinetic dose adjustments established; avoid or use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may reduce drug levels, but risks outweigh benefits; generally not recommended.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
Voltaren Arthritis Pain (diclofenac sodium topical gel 1%) is indicated for osteoarthritis of superficial joints (e.g., hands, knees). Apply 2-4 g per affected joint four times daily. Maximum total daily dose is 32 g for upper extremities and 16 g for lower extremities. Avoid contact with eyes and mucous membranes. Use for at least 4 weeks to assess efficacy. Do not apply to open wounds or infected areas. Concurrent use of oral NSAIDs increases risk of GI and renal toxicity; consider cumulative dose. Monitor for signs of local site reactions or systemic effects, especially in elderly or those with renal impairment.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Apply the gel to clean, dry skin only on the painful joint. Do not use on broken skin, cuts, or infections.,Use the enclosed dosing card to measure the correct amount: 2 to 4 grams per joint, up to four times daily.,Do not exceed 32 grams per day for hands, wrists, elbows, or 16 grams per day for knees, ankles, or feet.,Wash hands immediately after applying unless treating hands; then wait 1 hour before washing.,Allow the gel to dry for several minutes before covering the area with clothing or gloves.,Avoid applying sunscreen, cosmetics, lotions, or other topical products to the treated skin.,Do not use heat (e.g., heating pad) or bandage the treated area.,Inform your doctor if you have a history of stomach ulcers, bleeding, kidney disease, or are taking blood thinners.,Stop use and contact your doctor if you develop a rash, swelling, or worsening pain in the treated area.,Keep out of reach of children and pets. In case of accidental ingestion, seek medical attention.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VOLTAREN ARTHRITIS PAIN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
VOLTAREN ARTHRITIS PAIN is a NSAID (Topical) that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VOLTAREN ARTHRITIS PAIN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VOLTAREN ARTHRITIS PAIN is: Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VOLTAREN ARTHRITIS PAIN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VOLTAREN ARTHRITIS PAIN is classified as Category C. First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairme. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.